BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36701900)

  • 1. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
    Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
    EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
    Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
    Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study.
    Callender T; Imrie F; Cebere B; Pashayan N; Navani N; van der Schaar M; Janes SM
    PLoS Med; 2023 Oct; 20(10):e1004287. PubMed ID: 37788223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
    Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
    PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models.
    Liao W; Coupland CAC; Burchardt J; Baldwin DR; ; Gleeson FV; Hippisley-Cox J
    Lancet Respir Med; 2023 Aug; 11(8):685-697. PubMed ID: 37030308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection criteria for lung-cancer screening.
    Tammemägi MC; Katki HA; Hocking WG; Church TR; Caporaso N; Kvale PA; Chaturvedi AK; Silvestri GA; Riley TL; Commins J; Berg CD
    N Engl J Med; 2013 Feb; 368(8):728-36. PubMed ID: 23425165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
    Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
    PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening.
    Katki HA; Kovalchik SA; Petito LC; Cheung LC; Jacobs E; Jemal A; Berg CD; Chaturvedi AK
    Ann Intern Med; 2018 Jul; 169(1):10-19. PubMed ID: 29800127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
    Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
    Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
    Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
    JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing Different Approaches to Leveraging Historical Smoking Exposure Data to Better Select Lung Cancer Screening Candidates: A Retrospective Validation Study.
    Kats DJ; Adie Y; Tlimat A; Greco PJ; Kaelber DC; Tarabichi Y
    Nicotine Tob Res; 2021 Aug; 23(8):1334-1340. PubMed ID: 32974635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
    Robbins HA; Alcala K; Swerdlow AJ; Schoemaker MJ; Wareham N; Travis RC; Crosbie PAJ; Callister M; Baldwin DR; Landy R; Johansson M
    Br J Cancer; 2021 Jun; 124(12):2026-2034. PubMed ID: 33846525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial.
    Tammemägi MC; Ten Haaf K; Toumazis I; Kong CY; Han SS; Jeon J; Commins J; Riley T; Meza R
    JAMA Netw Open; 2019 Mar; 2(3):e190204. PubMed ID: 30821827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of lung cancer risk model (PLCO
    Lebrett MB; Balata H; Evison M; Colligan D; Duerden R; Elton P; Greaves M; Howells J; Irion K; Karunaratne D; Lyons J; Mellor S; Myerscough A; Newton T; Sharman A; Smith E; Taylor B; Taylor S; Walsham A; Whittaker J; Barber PV; Tonge J; Robbins HA; Booton R; Crosbie PAJ
    Thorax; 2020 Aug; 75(8):661-668. PubMed ID: 32631933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation.
    Field JK; Vulkan D; Davies MPA; Duffy SW; Gabe R
    Thorax; 2021 Feb; 76(2):161-168. PubMed ID: 33082166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.
    Tammemägi MC; Ruparel M; Tremblay A; Myers R; Mayo J; Yee J; Atkar-Khattra S; Yuan R; Cressman S; English J; Bedard E; MacEachern P; Burrowes P; Quaife SL; Marshall H; Yang I; Bowman R; Passmore L; McWilliams A; Brims F; Lim KP; Mo L; Melsom S; Saffar B; Teh M; Sheehan R; Kuok Y; Manser R; Irving L; Steinfort D; McCusker M; Pascoe D; Fogarty P; Stone E; Lam DCL; Ng MY; Vardhanabhuti V; Berg CD; Hung RJ; Janes SM; Fong K; Lam S
    Lancet Oncol; 2022 Jan; 23(1):138-148. PubMed ID: 34902336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Risk Prediction Model for Second Primary Lung Cancer.
    Choi E; Sanyal N; Ding VY; Gardner RM; Aredo JV; Lee J; Wu JT; Hickey TP; Barrett B; Riley TL; Wilkens LR; Leung AN; Le Marchand L; Tammemägi MC; Hung RJ; Amos CI; Freedman ND; Cheng I; Wakelee HA; Han SS
    J Natl Cancer Inst; 2022 Jan; 114(1):87-96. PubMed ID: 34255071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple model for predicting lung cancer occurrence in a lung cancer screening program: The Pittsburgh Predictor.
    Wilson DO; Weissfeld J
    Lung Cancer; 2015 Jul; 89(1):31-7. PubMed ID: 25863905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of lung cancer incidence on the low-dose computed tomography arm of the National Lung Screening Trial: A dynamic Bayesian network.
    Petousis P; Han SX; Aberle D; Bui AA
    Artif Intell Med; 2016 Sep; 72():42-55. PubMed ID: 27664507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Tammemägi MC; Cina K; Kitts AKB; Koop D; Petereit MA; Sargent M; Petereit DG
    Cancer; 2023 Dec; 129(24):3894-3904. PubMed ID: 37807694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.